Aclarion, Inc. (ACON)
After hours:
| Previous Close | 0.6900 |
| Open | 0.6900 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 4000 |
| Day's Range | 0.6000 - 0.6995 |
| 52 Week Range | 0.3800 - 4.0500 |
| Volume | |
| Avg. Volume | 41,531 |
| Market Cap | 5.082M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and i
- Newsfile
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event
Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.Event: Q1 Investor SummitDate: January 26th, 2023Presentation: January 26t
- GlobeNewswire
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine Service, the Neurospinal Disorders Pro
